Immunogenicity and Safety Study of SCB-2023 Vaccine as a Booster in Adults (clinicaltrials.gov) - Jul 3, 2023 - P3 | N=600 | Not yet recruiting | Sponsor: Clover Biopharmaceuticals AUS Pty Ltd
New P3 trial • Infectious Disease • Novel Coronavirus Disease
|